Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seelos Therapeutics Inc    SEEL

SEELOS THERAPEUTICS INC

(SEEL)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 06:01pm EDT

NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has granted a stock option to purchase 97,285 shares of common stock to Warren Wasiewski, MD, Seelos’ newly appointed Chief Scientific Officer.  This inducement award was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan, approved by the compensation committee of Seelos’ board of directors on July 28, 2019 and granted as an inducement material to Dr. Wasiewski’s employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price equal to $1.60, the closing price per share of Seelos’ common stock as reported by Nasdaq on August 12, 2019, the date of grant. The option is a non-qualified stock option and 1/4th of the shares vest on the one-year anniversary of Dr. Wasiewski’s commencement of employment and an additional 1/48th of the shares vest monthly thereafter over the next three years, in each case provided that Dr. Wasiewski remains continuously employed by Seelos through the applicable vesting date, inclusive.

Seelos is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward-Looking Statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the employees and equity plans. Risks and uncertainties include risks associated with the Company’s employees and equity plans, and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (NASDAQ: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SEELOS THERAPEUTICS INC
08/15SEELOS THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 5635..
AQ
08/14Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 563..
GL
08/14SEELOS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial..
AQ
08/06SEELOS THERAPEUTICS : to Ring Opening Bell at Nasdaq on August 12th
AQ
08/01SEELOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/01Seelos Therapeutics Reports Q2 2019 Pipeline Update
GL
07/17SEELOS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
07/17Seelos Therapeutics Announces Investigational New Drug Application Submission..
GL
07/15SEELOS THERAPEUTICS : Announces Receipt of a Grant for Funding of SLS-005 Progra..
PU
07/15Seelos Therapeutics Announces Receipt of a Grant for Funding of SLS-005 Progr..
GL
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -20,6 M
Net income 2019 -42,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,37x
P/E ratio 2020 -1,55x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 35,5 M
Chart SEELOS THERAPEUTICS INC
Duration : Period :
Seelos Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEELOS THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,00  $
Last Close Price 1,58  $
Spread / Highest target 406%
Spread / Average Target 280%
Spread / Lowest Target 153%
EPS Revisions
Managers
NameTitle
Raj Mehra Chairman, President, CEO & CFO
Richard W. Pascoe Director
Robin L. Smith Director
Daniel J. O'Connor Director
Brian Lian Director
Sector and Competitors
1st jan.Capitalization (M$)
SEELOS THERAPEUTICS INC722.92%36
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958